Search Result

Results for "

amino-terminal

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amino Acid Derivatives (1) Amyloid-β (2) Androgen Receptor (2) Apoptosis (2) Dengue Virus (1) Endothelin Receptor (1) Flavivirus (1) Fluorescent Dye (1) GCGR (3) GLP Receptor (2) GnRH Receptor (1) iGluR (1) LIM Kinase (LIMK) (1) Melanocortin Receptor (1) mTOR (2) NADPH Oxidase (1) Parasite (1) PPAR (2) Protease Activated Receptor (PAR) (1) Radionuclide-Drug Conjugates (RDCs) (2) Renin (1) Somatostatin Receptor (3)
By Research Areas:	Cancer (6) Cardiovascular Disease (1) Endocrinology (2) Infection (1) Inflammation/Immunology (1) Metabolic Disease (4) Neurological Disease (7)

By Targets:

Amino Acid Derivatives (1)

Amyloid-β (2)

Androgen Receptor (2)

Apoptosis (2)

Dengue Virus (1)

Endothelin Receptor (1)

Flavivirus (1)

Fluorescent Dye (1)

GCGR (3)

GLP Receptor (2)

GnRH Receptor (1)

iGluR (1)

LIM Kinase (LIMK) (1)

Melanocortin Receptor (1)

mTOR (2)

NADPH Oxidase (1)

Parasite (1)

PPAR (2)

Protease Activated Receptor (PAR) (1)

Radionuclide-Drug Conjugates (RDCs) (2)

Renin (1)

Somatostatin Receptor (3)

By Research Areas:

Cancer (6)

Cardiovascular Disease (1)

Endocrinology (2)

Infection (1)

Inflammation/Immunology (1)

Metabolic Disease (4)

Neurological Disease (7)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Targets Recommended: Amino Acid Decarboxylase Amino acid Transporter Amino Acid Derivatives JNK EAAT

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100348

EPI-001	Androgen Receptor PPAR Apoptosis	Cancer
EPI-001, a selective inhibitor of Androgen Receptor (AR), targets transactivation unit 5 (Tau-5) of the AR. EPI-001 can inhibit transactivation of the AR amino-terminal domain (NTD), with an IC₅₀ of ~6 μM. EPI-001 is also a selective modulator of PPARγ. EPI-001 is active against castration-resistant prostate cancer .

HY-160610A

Carbamoyl phosphate dilithium salt	Others	Others
Carbamoyl phosphate dilithium salt is an antisickling agent and plays a significant role in the urea cycle. Carbamoyl phosphate dilithium salt carbamylates the amino-terminal valine residues of hemoglobin S in erythrocytes, which interferes with the sickling phenomenon. Carbamoyl phosphate dilithium salt exhibits toxicity due to the lithium cation .

HY-P5912

GluN1(356-385)	iGluR	Neurological Disease
GluN1 (356-385) is an antigenic peptide against N-methyl-D-aspartate receptor (NMDAR) encephalitis. GluN1 (356-385) has the effect of reducing the density of surface NMDAR clusters in hippocampal neurons. GluN1 (356-385) can be used to study the pathogenesis of anti-NMDAR encephalitis .

HY-P3924

Agouti-Related Protein (54-82) (human) AGRP (54-82) (human)	Melanocortin Receptor	Neurological Disease
Agouti-Related Protein (54-82) (human) (AGRP (54-82) (human)) is an amino-terminal 54-82 fragment of agouti-related protein (AGRP) .

HY-20841

Boc-(2S)-Gly-4-pyranoyl (S)-2-((tert-Butoxycarbonyl)amino)-2-(tetrahydro-2H-pyran-4-yl)acetic acid; Boc-4-Pyranoyl-Gly-OH	Amino Acid Derivatives	Others
Boc-(2S)-Gly-4-pyranoyl ((S)-2-((tert-Butoxycarbonyl)amino)-2-(tetrahydro-2H-pyran-4-yl)acetic acid) is an amino-terminally protected glycine derivative that can be used to synthesize dipeptidyl peptidase IV with antidiabetic activity .

HY-P10668

Ac-EVKKQR-pNA	Dengue Virus Flavivirus	Infection
Ac-EVKKQR-pNA is a competitive chromogenic para-nitroanilide substrate corresponding to the P6-P1 segment amino-terminal to the NS2B-NS3 cleavage site but with a more reactive, hydrolytically cleavable, para-nitroanilide at the P1’ position. Ac-EVKKQR-pNA is promising for research of dengue 2 virus and flavivirus virus infection .

HY-P5455

S3 Fragment	LIM Kinase (LIMK)	Others
S3 Fragment is a biological active peptide. (This peptide contains the unique amino-terminal phosphorylation site of Xenopus ADF/cofilin, the LIM kinase (LIMK) phosphorylation site. LIMK1 is a key regulator of the actin cytoskeleton through its phosphorylation of ADF/cofilin at serine-3 for inactivation. This peptide is a fragment of the S3 peptide containing the serine-3 sequence of ADF/cofilin that has been widely used as an effective competitive inhibitor of LIMK1.)

HY-100348R

EPI-001 (Standard)	Androgen Receptor PPAR Apoptosis	Cancer
EPI-001 (Standard) is the analytical standard of EPI-001. This product is intended for research and analytical applications. EPI-001, a selective inhibitor of Androgen Receptor (AR), targets transactivation unit 5 (Tau-5) of the AR. EPI-001 can inhibit transactivation of the AR amino-terminal domain (NTD), with an IC₅₀ of ~6 μM. EPI-001 is also a selective modulator of PPARγ. EPI-001 is active against castration-resistant prostate cancer .

HY-P99527

Vanutide cridificar ACC-001; PF 05236806	Amyloid-β	Neurological Disease
Vanutide cridificar (ACC-001) is an aminoterminal Aβ1-7 peptide conjugate. Vanutide cridificar can be used for Alzheimer's disease (AD) research .

HY-P5329

r8-Gly-Noxa A BH3	NADPH Oxidase	Others
r8-Gly-Noxa A BH3 is a biological active peptide. (This cell permeable peptide is derived from the BH3 domain (a death domain) of Noxa A, amino acid residues 17 to 36. Eight D-Arginine residues and a Glycine linker residue are added to the amino terminal of the peptide.)

HY-P2380

PAR3 (1-6) (human) TFRGAP	Protease Activated Receptor (PAR)	Inflammation/Immunology
PAR3 (1-6) is a synthetic peptide agonist of proteinase-activated receptor 1 (PAR1) that corresponds to residues 1-6 of the amino terminal tethered ligand sequence of human PAR3 and residues 39-44 of the full-length human sequence. PAR3 (1-6) activates p42/44 MAPK signaling in fibroblasts expressing PAR1, but not PAR3, an effect that can be blocked by the PAR1 antagonist RWJ 56110.

HY-P4154

Bevonescein ALM-488	Fluorescent Dye	Neurological Disease Cancer
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .

HY-P2075

EMD 55068	Renin	Endocrinology
EMD 55068 is a renin antagonist. EMD 55068 inhibits the uptake of taurocholate .

HY-P10472

Azaline B	GnRH Receptor	Endocrinology
Azaline B is an antagonist for gonadotropin-releasing hormone (GnRH) with IC₅₀ of 1.37 nM, Azaline B can be used in research of sex hormone-related pathological states, ovulation induction and male contraception .

HY-P4757

N1-Glutathionyl-spermidine disulfide	Parasite	Others
N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-P10876

mcK6A1	Amyloid-β	Neurological Disease
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .

HY-P5984A

Thioether-cyclized helix B peptide, CHBP TFA	mTOR	Others
Thioether-cyclized helix B peptide, CHBP (TFA) is the TFA form of Thioether-cyclized helix B peptide, CHBP (HY-P5984). Thioether-cyclized helix B peptide, CHBP (TFA) can improve metabolic stability and renoprotective effect through inducing autophagy via inhibition of mTORC1 and activation of mTORC2 .

HY-P4146

Survodutide BI 456906	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P5984

Thioether-cyclized helix B peptide, CHBP	mTOR	Others
Thioether-cyclized helix B peptide, CHBP can improve metabolic stability and renoprotective effect through inducing autophagy via inhibition of mTORC1 and activation of mTORC2 .

HY-P4146A

Survodutide TFA BI 456906 TFA	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P2434

AP102	Somatostatin Receptor	Neurological Disease Metabolic Disease Cancer
AP102 is a dual SSTR2/SSTR5-specific somatostatin analog (SSA). AP102 is a disulfide-bridged octapeptide SSA containing synthetic iodinated amino acids. AP102 binds with subnanomolar affinity to SSTR2 and SSTR5 (IC₅₀: 0.63 and 0.65 nM, respectively). AP102 does not bind to SSTR1 or SSTR3. AP102 can be used for acromegaly and neuroendocrine tumors research .

HY-P5362A

NODAGA-LM3 TFA	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
NODAGA-LM3 TFA can be labeled by ⁶⁸Ga for PET imaging. ⁶⁸Ga-NODAGA-LM3 TFA is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas. NODAGA-LM3 TFA can be labeled with [68Ga] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P5362

NODAGA-LM3	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
NODAGA-LM3 can be labeled by ⁶⁸Ga for PET imaging. ⁶⁸Ga-NODAGA-LM3 is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas. NODAGA-LM3 can be labeled with [68Ga] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-105168

TAK 044	Endothelin Receptor	Cardiovascular Disease
TAK 044 is an antagonist of Endothelin Receptor. TAK 044 strongly inhibits ET-induced deterioration in various animal models. TAK 044 can be used in study ET-related diseases such as acute myocardial infarction,acute renal failure, acute hepatic malfunction, and subarachnoid hemorrhage .

Cat. No.	Product Name	Target	Research Area